Efficacy of B cell depletion therapy for murine joint arthritis flare is associated with increased lymphatic flow

被引:56
作者
Li, Jie [1 ]
Ju, Yawen [1 ]
Bouta, Echoe M. [1 ]
Xing, Lianping [1 ]
Wood, Ronald W. [1 ]
Kuzin, Igor [1 ]
Bottaro, Andrea [1 ]
Ritchlin, Christopher T. [1 ]
Schwarz, Edward M. [1 ]
机构
[1] Univ Rochester, Ctr Musculoskeletal Res, Med Ctr, Sch Med & Dent, Rochester, NY 14642 USA
来源
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷 / 01期
关键词
TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; TRANSGENIC MICE; RITUXIMAB; NODE; LYMPHANGIOGENESIS; MODEL; METHOTREXATE; INFLAMMATION; SYSTEM;
D O I
10.1002/art.37709
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective B cell depletion therapy ameliorates rheumatoid arthritis by mechanisms that are incompletely understood. Arthritis flare in tumor necrosis factor (TNF)transgenic mice is associated with efferent lymph node (LN) collapse, triggered by B cell translocation into lymphatic spaces and decreased lymphatic drainage. The aim of this study was to examine whether the efficacy of B cell depletion therapy is associated with restoration of lymphatic drainage due to removal of obstructing nodal B cells. Methods We used contrast-enhanced magnetic resonance imaging, indocyanine green near-infrared imaging, and intravital immunofluorescence imaging to longitudinally assess synovitis, lymphatic flow, and cell migration in lymphatic vessels in TNF-transgenic mice. We conducted tests to determine whether the efficacy of B cell depletion therapy is associated with restoration of lymphatic draining and cell egress from arthritic joints. Results Unlike active lymphatics to normal and prearthritic knees, afferent lymphatic vessels to collapsed LNs in inflamed knees do not pulse. Intravital immunofluorescence imaging demonstrated that CD11b+ monocyte/macrophages in lymphatic vessels afferent to expanding LNs travel at high velocity (mean +/- SD 186 +/- 37 mu m/second), while these cells are stationary in lymphatic vessels afferent to collapsed popliteal LNs. B cell depletion therapy for arthritis flares in TNF-transgenic mice significantly decreased knee synovium volume (by 50% from the baseline level) and significantly increased lymphatic clearance compared with placebo (P < 0.05). This increased lymphatic drainage restored macrophage egress from inflamed joints without recovery of the lymphatic pulse. Conclusion These results support a novel mechanism in which B cell depletion therapy for joint arthritis flares lessens inflammation by increasing lymphatic drainage and subsequent migration of cells and cytokines from the synovial space.
引用
收藏
页码:130 / 138
页数:9
相关论文
共 35 条
[1]
Response to Rituximab in Patients With Rheumatoid Arthritis in Different Compartments of the Immune System [J].
Boumans, Maria J. H. ;
Thurlings, Rogier M. ;
Gerlag, Danielle M. ;
Vos, Koen ;
Tak, Paul P. .
ARTHRITIS AND RHEUMATISM, 2011, 63 (11) :3187-3194
[2]
Rituximab treatment in rheumatoid arthritis: how does it work? [J].
Boumans, Maria J. H. ;
Tak, Paul P. .
ARTHRITIS RESEARCH & THERAPY, 2009, 11 (06)
[3]
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis [J].
Buch, Maya H. ;
Smolen, Josef S. ;
Betteridge, Neil ;
Breedveld, Ferdinand C. ;
Burmester, Gerd ;
Doerner, Thomas ;
Ferraccioli, Gianfranco ;
Gottenberg, Jacques-Eric ;
Isaacs, John ;
Kvien, Tore K. ;
Mariette, Xavier ;
Martin-Mola, Emilio ;
Pavelka, Karel ;
Tak, Paul P. ;
van der Heijde, Desiree ;
van Vollenhoven, Ronald F. ;
Emery, Paul .
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) :909-920
[4]
Targeting joint lymphatic function [J].
Jenny Buckland .
Nature Reviews Rheumatology, 2011, 7 (7) :376-376
[5]
Lymphatic system: a vital link between metabolic syndrome and inflammation [J].
Chakraborty, Sanjukta ;
Zawieja, Scott ;
Wang, Wei ;
Zawieja, David C. ;
Muthuchamy, Mariappan .
LYMPHATICS IN THE DIGESTIVE SYSTEM: PHYSIOLOGY, HEALTH, AND DISEASE, 2010, 1207 :E94-E102
[6]
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].
Cohen, Stanley B. ;
Emery, Paul ;
Greenwald, Maria W. ;
Dougados, Maxime ;
Furie, Richard A. ;
Genovese, Mark C. ;
Keystone, Edward C. ;
Loveless, James E. ;
Burmester, Gerd-Ruediger ;
Cravets, Matthew W. ;
Hessey, Eva W. ;
Shaw, Timothy ;
Totoritis, Mark C. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806
[7]
Profiling of rheumatoid arthritis associated autoantibodies [J].
Conrad, Karsten ;
Roggenbuck, Dirk ;
Reinhold, Dirk ;
Doerner, Thomas .
AUTOIMMUNITY REVIEWS, 2010, 9 (06) :431-435
[8]
Cueni Leah N., 2008, Lymphatic Research and Biology, V6, P109, DOI 10.1089/lrb.2008.1008
[9]
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis [J].
Edwards, JCW ;
Szczepanski, L ;
Szechinski, J ;
Filipowicz-Sosnowska, A ;
Emery, P ;
Close, DR ;
Stevens, RM ;
Shaw, T .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) :2572-2581
[10]
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) [J].
Emery, P. ;
Deodhar, A. ;
Rigby, W. F. ;
Isaacs, J. D. ;
Combe, B. ;
Racewicz, A. J. ;
Latinis, K. ;
Abud-Mendoza, C. ;
Szczepanski, L. J. ;
Roschmann, R. A. ;
Chen, A. ;
Armstrong, G. K. ;
Douglass, W. ;
Tyrrell, H. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (09) :1629-1635